AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04385810 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ophthalmologic exam
Description: Direct exam and Slit lamp exam Shirmer test Retinophotography At inclusion, day 7, day 14 and discharge from hospital
Study NCT03455179 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Slow-speed traditional resistance training
Description: The training session will consist in a general warm-up, 6 resistance exercises, including 2 upper limb exercises (elbow curl and chest press), 2 lower limb exercises (lunge and standing hip abduction), and 2 exercises combining both upper and lower limbs at the same time (squat plus upright rowing and squat plus shoulder press) and finally the cooldown routine.The participants will perform in each training session 6 submaximal repetitions equivalent to 85% of the one-repetition maximum (1RM) and 3-4 sets per exercise (high intensity training sessions).
Study NCT03455179 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-speed resistance training
Description: The participants will perform the same exercises than the TRADICIONAL group with12 submaximal repetitions equivalent to 40-50% 1RM (low-intensity) and 3-4 sets per exercise.
Study NCT03455179 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multicomponent training
Description: Participants will perform, in this order, balance exercises followed by resistance/coordination, aerobic/coordination and flexibility exercises in each session. The balance training will consist in static, dynamic and proactive balance exercises. In the resistance training block, the participants will perform 3-4 sets of 15 submaximal repetitions Participants will perform 2 resistance exercises (squat plus upright rowing and lunge) at traditional slow-speed (2s of concentric contraction and 2s of eccentric contraction).The intensity of the aerobic block will progress from 65 to 85% of the maximum heart rate over the training weeks.
Study NCT01939600 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Starch-free breakfast
Description: Starch-free breakfast alone
Study NCT01939600 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hi-Maize 260
Description: Starch-free breakfast plus 55.3g Hi-Maize 260
Study NCT01939600 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hylon VII
Description: Starch-free breakfast plus 56.9g Hylon VII
Study NCT00957320 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG-asparaginase
Description: Subjects will receive PEG-asparaginase at a fixed weekly dose, as per published reports in relapsed childhood ALL.
Study NCT02185326 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Growth hormone (Norditropin, Novo nordisk)
Description: Growth hormone (Norditropin, Novo nordisk) was administrated on day 6 of HMG stimulation daily in a dose of 2.5 mg S.C. till the day of hCG administration.
Study NCT03554733 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ReInventing Yourself after SCI
Description: 6-week, manualized, cognitive-behaviorally based group educational intervention
Study NCT04267679 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol
Description: 25 mg full-spectrum CBD soft gel capsules
Study NCT00478816 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fluad H5N1 Pandemic Influenza Vaccine
Description: Two 0.5 mL doses of MF59-adjuvanted A/Vietnam/1194/2004 (H5N1 Clade 1) hemagglutinin (HA) subvirion influenza vaccine, containing 7.5 μg of H5N1 antigen,administered 3 weeks apart, IM in the deltoid muscle, preferably of the non-dominant arm.
Study NCT04386655 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brain Injur Coping Skills - Telemedicine
Description: BICS sessions (both in-person and telemedicine) will occur once a week for 12 weeks. Each session will last two hours.~Modules of BICS include: Introduction to Brain Injury, Expectations for Recovery, Tips on Managing Challenging Problems, Learning about Depression after the Brain Injury, The 4 R's of Stress Management, Communicating Effectively with Professionals
Study NCT04386655 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brain Injur Coping Skills - Telemedicine
Description: BICS sessions (both in-person and telemedicine) will occur once a week for 12 weeks. Each session will last two hours.~Modules of BICS include: Introduction to Brain Injury, Expectations for Recovery, Tips on Managing Challenging Problems, Learning about Depression after the Brain Injury, The 4 R's of Stress Management, Communicating Effectively with Professionals
Study NCT02888041 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dinoprostone
Description: In case of failure of cervical ripening after a first intravaginal delivery device of Dinoprostone (Propess® 10 mg), patients receive a second Propess®, followed by Oxytocin 5U.I/ml (Syntocinon®) (if necessary) and epidural analgesia if desired by the patient.
Study NCT02888041 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocine
Description: In case of failure of cervical ripening after a first intravaginal delivery device of Dinoprostone (Propess® 10mg), patients receive directly Oxytocin 5U.I/ml (Syntocinon®) and epidural analgesia if desired by the patient.
Study NCT02920008 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: guadecitabine
Description: In Cycle 1, guadecitabine will be given for 10 days on Days 1-5 and Days 8-12. In Cycle 2, the guadecitabine dose will be 60 mg/m\^2 for either 10 days (Days 1-5 and 8-12) or 5 days (Days 1-5 only) based on assessment of disease response, and hematological recovery by Day ≥28.
Study NCT02920008 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Treatment Choice (TC)
Description: * High intensity: intermediate or high dose cytarabine (HiDAC); mitoxantrone, etoposide, and cytarabine (MEC); or fludarabine, cytarabine, G-CSF, +/- idarubicin (FLAG/FLAG-Ida).~* Low intensity: low dose cytarabine (LDAC), decitabine, or azacitidine.~* Best Supportive Care (BSC).
Study NCT03325634 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03325634 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT03325634 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT03325634 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Description: Undergo SBRT
Study NCT04454866 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single injection of penehyclidine
Description: A dose of penehyclidine hydrochloride (0.5 mg/5 ml) is injected intravenously before anesthesia induction. A patient-controlled intravenous analgesia pump is provided after surgery, which is established with a mixture of placebo (normal saline 5 ml), sufentanil (1.25-1.5 ug/kg) and tropisetron (10 mg), diluted with normal saline to 100 ml, and programmed to administer a continuous infusion at a rate of 2 ml/h for 48 hours.
Study NCT04454866 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Continuous infusion of penehyclidine
Description: A dose of penehyclidine hydrochloride (0.25 mg/5 ml) is injected intravenously before anesthesia induction. A patient-controlled intravenous analgesia pump is provided after surgery, which is established with a mixture of penehyclidine hydrochloride (0.25 mg/5 ml), sufentanil (1.25-1.5 ug/kg) and tropisetron (10 mg), diluted with normal saline to 100 ml, and programmed to administer a continuous infusion at a rate of 2 ml/h for 48 hours.
Study NCT03668119 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days
Study NCT03668119 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Specified dose on specified days
Study NCT04454866 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A dose of placebo (normal saline 5 ml) is injected intravenously before anesthesia induction. A patient-controlled intravenous analgesia pump is provided after surgery, which is established with a mixture of placebo (normal saline 5 ml), sufentanil (1.25-1.5 ug/kg) and tropisetron (10 mg), diluted with normal saline to 100 ml, and programmed to administer a continuous infusion at a rate of 2 ml/h for 48 hours.
Study NCT01320046 — intervention group
Intervention type: OTHER
Intervention: Questionnaires, gynecological exam , vaginal smear, and measurement of urine leakage
Description: Patients will undergo the following evaluation:~1. Questionnaires- age, medical background, BMI, UI characteristics , usage of pads, other hygiene practices,hormonal therapy, presence of allergic tendency and history etc.~2. Medical history.~3. Gynecological exam including bladder/rectum/uterine prolapse, vaginal atrophy, discharge, findings of VCD (as part of the usual evaluation in the clinic).~4. Vaginal smear: this will be used for vaginal pH measurement and for wet mount, which will assess estrogen deficiency, yeast infection and other inflammatory conditions. Vaginal smears are done as part of the usual evaluation in the clinic.~5. Evaluation of the severity of urinary incontinence will be done by collection and weighting of pads during 24 hours.
Study NCT01692340 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Isotopically labeled lycopene, phytoene or phytofluene
Description: We will administer 10 mg of labeled carotenoid mixed with olive oil and spread on an English muffin for consumption by participants.
Study NCT00517712 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Single agent arsenic trioxide
Description: duration of maintenance therapy, 6 months versus 12 months
Study NCT02478619 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: IMT group
Description: Patients will be instructed to do a daily inspiratory muscle training at home with the preset load at 50% of the maximal inspiratory pressure, during 30 minutes for 4 weeks before bariatric surgery.~They will also receive the routine physical therapy in the post operative period.
Study NCT02478619 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control group
Description: Patients will be instructed to do a daily inspiratory muscle training at home with the minimal inspiratory load of the respiratory resistance device, during 30 minutes for 4 weeks before bariatric surgery. They will also receive the routine physical therapy in the post operative period.
Study NCT01386528 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nonacog beta pegol
Description: The patients will receive nonacog beta pegol at screening just prior to and during surgical intervention, administered intravenously (into the vein).
Study NCT05888636 — intervention group
Intervention type: OTHER
Intervention: ChIP-seq, NGS, ATAC-seq
Description: Bone narrow sampling
Study NCT00951483 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quetiapine-XR
Description: Quetiapine-XR (Seroquel-XR) 50-300mg daily for 12 weeks.
Study NCT04973865 — intervention group
Intervention type: OTHER
Intervention: Validation & reliability
Description: Translated version of IPAQ(SF) validation \& Reliability
Study NCT00562887 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: every 4 weeks, IV
Study NCT00562887 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ABT-874
Description: 400 mg IV every 4 weeks
Study NCT00562887 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ABT-874
Description: 700 mg IV every 4 weeks
Study NCT02014714 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: Drug: Morphine Depending on the randomization schedule, 0.1mg of morphine or will be added to the intrathecal mixture.
Study NCT02014714 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: Drug: Fentanyl 40mcg Depending on the randomization schedule, 40μg of fentanyl will be added to the intrathecal mixture.
Study NCT03335033 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Contrast-enhanced ultrasound
Description: Subjects will receive a low mechanical index (0.17-0.20) imaging during ultrasound contrast agent intravenous infusion. Real-time cine-loop including longitudinal and transverse images obtained at least 3 seconds before and 5 minutes after the appearance of the contrast effect in the lumen of the carotid artery will be acquired and digitally stored for offline analysis. Also use of a 3D ultrasound transducer to evaluate the feasibility of using US images with contrast to assess the residual diameter of the diseased vessel. Specifically, two 3D acquisitions of each lesion would be obtained after contrast has been injected.
Study NCT01870973 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: root canal treatment, anesthesia, pain medications, and antibiotic
Description: Root canal treatment is the intervention (no initial treatment versus initial treatment). We are not studying a drug or device.
Study NCT01870973 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: no root canal treatment, anesthesia, pain medications, and antibiotic
Study NCT02671799 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VenTouch System Implant
Description: The VenTouch System is intended for use in the treatment of functional MR (FMR) in adults who are symptomatic despite optimal medical management. It is intended for subjects with FMR with essentially normal leaflet anatomy and motion, with mitral valve regurgitation attributable mainly to annular dilatation with or without papillary muscle displacement. It is not intended to treat structural defects/degeneration of the mitral valve. The VenTouch System is used to reshape the base of the heart to bring the mitral valve leaflets into better coaptation. By doing so, it brings the mitral valve leaflets closer, allowing proper closure of the valve, and reducing or eliminating MR. There is provision of support to the ventricular myocardium below the annulus as well as the annulus, so the VenTouch System may allow long-term ventricular remodeling with positive impact on the functionality of the mitral valve.
Study NCT02623933 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: MRI assisted focal boost with HDR monotherapy
Description: Prior to brachytherapy treatment, a multiparametric MRI will be obtained for identification of the dominant intraprostatic lesion (DIL) and fused with the preplanning transrectal ultrasound. A total of 19 Gy will be prescribed to the prostate, organ at risk limits will be observed and up to 22.5 Gy can be delivered to the DIL
Study NCT03335033 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Shear Wave Elastography
Description: Shear wave elastography will be performed with the General Electric Logiq E9 scanner acquiring images of each plaque in the longitudinal and transverse imaging planes. In each plane 10 measurements will be made and the in-phase/quadrature (IQ) data will be saved for further analysis. The plaque area in the imaging plane will be user-defined to extract the wave velocity values for a ROI analysis.
Study NCT03335033 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound Examination
Description: A standard carotid US examination using Duplex imaging will performed using a linear array transducer to obtain longitudinal and transverse images. All ultrasound measurements will be made by a trained registered vascular technologist. Severity of stenosis of the plaque will be measured based on established protocol and guidelines.
Study NCT01559298 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin (80 mg/d) + clopidogrel (75 mg/d)
Description: Aspirin (80 mg/d) + clopidogrel (75 mg/d) Aspirin therapy will start at least 24 hrs before the TAVI procedure and continued for at least 6 months. Clopidogrel therapy will start within 24 hrs before the TAVI procedure in cases where a transfemoral approach is used and within 24 hrs after the TAVI procedure in cases where a transapical approach is used. The initial dose of clopidogrel will be of 300 mg followed by 75 mg/die. The duration of clopidogrel treatment will be of 3 months. Patients will be followed either by phone contact or clinical visits at 1- and 12-month follow-up.
Study NCT01559298 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: Aspirin (80 mg/d) Aspirin therapy will start at least 24 hrs before the TAVI procedure and continued for at least 6 months.
Study NCT03516448 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gan Fu Le Tablets
Description: 6 Tablets，tid,po
Study NCT03516448 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Gan Fu Le Tablets
Description: 6 Tablets，tid,po
Study NCT03516448 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tyroserleutide for injection
Description: 6mg/d, 5days,ivgtt
Study NCT03516448 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0mg/d, 5days,ivgtt
Study NCT02429882 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Brodalumab 210 mg
Description: 210 mg brodalumab will be administered subcutaneously
Study NCT02429882 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered subcutaneously
Study NCT01392560 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 10773
Description: Oral once daily
Study NCT03809481 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danaparoid Sodium
Description: inhibits thrombin generation by indirect anti-Xa inhibition and direct inhibition of factor IX activation
Study NCT03809481 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Argatroban
Description: Synthetic direct thrombin inhibitor
Study NCT03071692 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: K-877
Description: 0.2mg tablet
Study NCT03071692 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: K-877 matching placebo tablet
Study NCT00649194 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabeprazole Sodium Delayed-Release Tablets 20 mg
Description: 20mg, single dose fed
Study NCT00649194 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aciphex® Tablets 20 mg
Description: 20mg, single dose fed
Study NCT00088231 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib Mesylate (Gleevec)
Description: 600 mg by mouth every day (for AML, CML-BP) for a 28 day cycle.~400 mg by mouth every day (for AMM) for a 28 day cycle.
Study NCT00088231 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PTK 787 (vatalanib)
Description: For 1 week prior to receipt of the study combination regimen, all patients will receive single agent PTK 787 at the dose specified for that dose level of the study combination regimen to allow stabilization of PTK 787 levels.~Starting dose: 250 mg by mouth every day for a 28 day cycle.
Study NCT03651089 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SP16
Description: subcutaneous injection of experimental anti-inflammatory drug
Study NCT03651089 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: subcutaneous injection of sterile saline
Study NCT00682734 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metoclopramide
Description: metoclopramide 20 mg
Study NCT00682734 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metoclopramide
Description: metoclopramide 40 mg
Study NCT00682734 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metoclopramide
Description: metoclopramide 10 mg
Study NCT00682734 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diphenhydramine 25mg
Description: Diphenhydramine 25mg, administered as an intravenous drip over 20 minutes
Study NCT00682734 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diphenhydramine 25mg
Description: Diphenhydramine 25mg, administered as an intravenous drip over 20 minutes
Study NCT04100005 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: There is no intervention for this study.
Study NCT03715933 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INBRX-109
Description: Tetravalent DR5 Agonist Antibody
Study NCT03715933 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Chemotherapy
Study NCT03715933 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Chemotherapy
Study NCT03715933 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Chemotherapy
Study NCT03715933 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil
Description: Chemotherapy
Study NCT03715933 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Chemotherapy
Study NCT03715933 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Chemotherapy
Study NCT03753061 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aspiration Catheter
Description: Patients will be treated for mechanical recanalization with Aspiration Catheter within 8 hours after stroke onset plus standard medical management.
Study NCT03753061 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Solitaire FR
Description: Patients will be treated for mechanical recanalization with Solitaire FR within 8 hours after stroke onset plus standard medical management.
Study NCT01414387 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Carotid filter
Description: Patients randomized to this group will receive filter devices to prevent cerebral embolization during carotid stenting, assessed by intraoperative transcranial Doppler and postoperative cerebral DW-MRI.~The filter used for this trial is the RX accunet embolic protection system manufactured by abbott.